Non-Fucosylated Anti-Human Cell adhesion molecule 2 (2B11) Therapeutic Antibody, an ADCC-
Enhanced Biobetter (CAT#: BioBet-622ZP) Datasheet
Cell adhesion molecule 2
ADCC-Enhanced anti-Cell adhesion molecule 2 (2B11) is a non-fucosylated therapeutic biobetter
All services and products are only for lab research, not for individuals.
Creative Biolabs has established a team of customer support scientists
ready to discuss ADCC/CDC optimization strategies, antibody production,
bioinformatics analysis and other molecular biology/biotechnology
antibody engineered by Creative Biolabs' Afuco™ technology platform. By reducing the
fucosylation of the Fc region, the ADCC-enhanced antibody shows an increased binding affinity
for the FcyR receptor on immune effector cells.
More specifically, the afucosylated therapeutic biobetter antibody was generated by recombinant
DNA technology. It has been produced in CHO cells that are deficient for fucosylation and
purified by affinity chromatography with protein G. The absence of the fucose residue from the
N-glycans of IgG-Fc results in dramatic enhancement of antibody-dependent cellular
Therapeutic antibody; biobetter
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced
rituximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your
choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
(BioBet-622ZP) Non-Fucosylated An